CANFNYSEPharmaceutical PreparationsFiscal year ends December 31

Can-Fite BioPharma Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026

$1.89+0.13 (+7.39%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Dec 31, 2025

Can-Fite BioPharma reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Can-Fite BioPharma's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Can-Fite BioPharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-3000 reverse split on Mar 26, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CANF.

Revenue growth-39.9% · median -10.7%

Operating margin-2456.8% · median -5168.8%

Net margin-2426.7% · median -4732.5%

Company	Revenue	Growth
YARW	$476.00K	-2.1%
CANF	$405.00K	-39.9%
LIPO	$389.78K	-19.4%
XTLB	–	–
SCNX	–	–
ADXN	–	–

Company

Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 5
Held by institutions: 1.9%
Auditor: KOST FORER GABBAY& KASIERER
SEC CIK: 1536196

Advertisement
300 × 250